Erleada (Apalutamide) Patent Expiration, LOE Window & CMS Spending
Erleada (Apalutamide) by Johnson & Johnson: FDA Orange Book core substance LOE 2033-06-04 (last listed 2041-01-14), 1 AB generics, $1.44B 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Johnson & Johnson |
| FDA Application & Pathway | N210951 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2033-06-04 |
| Last Listed Patent or Exclusivity Date | 2041-01-14 |
| Orange Book Patents (*PED Extensions) | 14 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $1.44B |
| 2024 Medicare Part D Spend | $1.39B |
| 2024 Medicaid Spend | $52.1M |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 16.2% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.